Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 7.8% – Here’s What Happened

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares traded down 7.8% during trading on Wednesday . The company traded as low as $3.90 and last traded at $3.90. 9,134 shares were traded during trading, a decline of 90% from the average session volume of 90,658 shares. The stock had previously closed at $4.23.

Qualigen Therapeutics Trading Down 3.5 %

The stock has a fifty day moving average of $5.13 and a 200 day moving average of $8.42.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.